News | June 04, 2008

AngioScore Starts Enrollment in Coronary Artery Bifurcation Trial

June 5, 2008 – AngioScore started enrollment in the AngioSculpt Scoring Balloon Catheter Multi-Center Coronary Bifurcation Study (AGILITY), designed to compare AngioSculpt Scoring Balloon Catheters in treating bifurcation lesions over conventional angioplasty balloon catheters.

The AngioSculpt Scoring Balloon Catheter Multi-Center Coronary Bifurcation Study (AGILITY) is a prospective, multicenter, single arm study evaluating the AngioSculpt as the primary treatment of the side-branch vessel along with an approved drug-eluting stent for the main branch vessel. Patients will be followed at one month for safety outcomes and at nine months for clinical evidence of restenosis (TLR).

The AngioSculpt Scoring Balloon Catheters use nitinol elements for circumferential scoring of plaque, designed to lead to predictable luminal enlargement across a wide range of lesion types, while avoiding geographic miss through their unique anti-slippage properties. The AngioSculpt catheters provide the versatility and effectiveness of a new technology together with the simplicity and deliverability of raditional high-performance balloon catheters.

The AGILITY trial will enroll 100 patients with coronary bifurcation lesions at eight premier interventional cardiology programs in the U.S. and follow these patients for nine months. Jeffrey Moses, M.D., professor of Medicine and Director of the Cardiac Catheterization Laboratories at Columbia University Medical Center, will serve as the overall trial Principal Investigator.

The AngioSculpt is engineered to improve upon conventional angioplasty balloon catheters for the treatment of challenging lesions because of its ability to achieve more predictable luminal expansion and a lower rate of dissection. This may be particularly valuable in bifurcation side-branch lesions – potentially minimizing the need to place a second stent in the branch vessel.

In January 2007, the AngioSculpt Percutaneous Transluminal Coronary Angioplasty (PTCA) Scoring Balloon Catheter received FDA pre-market application (PMA) approval for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.

For more information:

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Medtronic, IN.PACT Admiral DCB, drug-coated balloon, below-the-knee, European BTK IN.PACT clinical study, peripheral artery disease, PAD, launch
News | Peripheral Artery Disease (PAD)| March 09, 2017
Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
Overlay Init